Analytical Data
-
基因名
KIR2DL1
- Application
-
别名
HLA-C;HLAC;HLA class I histocompatibility antigen. C alpha chain
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P43626
-
表达区间
1-245aa
-
氨基酸序列
MSLLVVSMAC VGFFLLQGAW PHEGVHRKPS LLAHPGPLVK SEETVILQCW SDVMFEHFLL HREGMFNDTL RLIGEHHDGV SKANFSISRM TQDLAGTYRC YGSVTHSPYQ VSAPSDPLDI VIIGLYEKPS LSAQPGPTVL AGENVTLSCS SRSSYDMYHL SREGEAHERR LPAGPKVNGT FQADFPLGPA THGGTYRCFG SFHDSPYEWS KSSDPLLVSV TGNPSNSWPS PTEPSSKTGN PRHLH
-
分子量
26 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIR2DL1 (Killer Cell Immunoglobulin-like Receptor 2DL1) is a pivotal receptor expressed on natural killer (NK) cells and plays a crucial role in the regulation of immune responses by recognizing specific HLA class I molecules, particularly HLA-C alleles. The understanding of KIR2DL1 and its interactions with HLA-C is essential for elucidating the mechanisms underlying immune evasion in various diseases, including viral infections and cancer. Research has shown that the engagement of KIR2DL1 not only inhibits NK cell activation but also modulates the overall immune landscape, potentially affecting treatment outcomes in immunotherapy. Recombinant KIR2DL1 protein is a valuable tool for studying these interactions in detail. It allows researchers to investigate the structural and functional properties of KIR2DL1, explore its ligand-binding characteristics, and assess its signaling pathways. Furthermore, recombinant KIR2DL1 can be utilized in various assays to understand its role in NK cell tolerance and activation, facilitating the development of novel therapeutic strategies aimed at enhancing anti-tumor immunity. Understanding the biology of KIR2DL1 through recombinant protein studies holds potential implications for improving immunotherapeutic approaches and guiding personalized medicine in the treatment of cancers and chronic infections. As research progresses, insights gained from KIR2DL1 recombinant protein studies may pave the way for innovative immunotherapeutic interventions by better harnessing the body’s natural immune responses.
